Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. explains the impact of Entrectinib and the STARTRK-2 trial on clinical practice and future clinical trials. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Advertisement